Related Experiment Videos
Danazol in autoimmune haemolytic anaemia
J M Pignon1, E Poirson, H Rochant
1Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France.
British Journal of Haematology
|February 1, 1993
Summary
Danazol combined with prednisone offers effective long-term treatment for warm antibody autoimmune hemolytic anemia (AIHA), reducing the need for splenectomy and shortening prednisone therapy duration.
Area of Science:
- Hematology
- Immunology
- Pharmacology
Background:
- Warm antibody autoimmune hemolytic anemia (AIHA) is a condition where the immune system attacks red blood cells.
- Treatment often involves prednisone, but some patients are refractory or relapse, requiring further interventions like splenectomy.
Purpose of the Study:
- To evaluate the efficacy and safety of Danazol in combination with prednisone for treating warm AIHA.
- To assess Danazol's impact on prednisone duration and the need for splenectomy.
Main Methods:
- Adult patients with warm AIHA were treated with Danazol and prednisone.
- Patients included those at initial presentation, those with refractory AIHA, and those relapsing after prednisone response.
- Follow-up averaged 21 months.
Main Results:
- 80% of patients at initial presentation showed long-lasting responses.
- 60% of patients with refractory or relapsed AIHA also achieved long-lasting responses.
- Minimal side-effects were observed during treatment.
Conclusions:
- Danazol plus prednisone is an effective treatment for warm AIHA, yielding high response rates.
- Adding Danazol may reduce prednisone therapy duration and the requirement for splenectomy.
- The combination therapy demonstrates a favorable safety profile.